A Phase 2 interventional study of UCB7665 in Thrombocytopenia, sponsored by UCB Biopharma SRL. Completed at 29 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-29.
Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Thrombocytopenia with a site in Poland — 3 open to participants now, 4 under way, 3 of them phase 3. Thrombocytopenia · Poland.
Among the 21 studies in Thrombocytopenia with a site in Poland, this one is the 16th largest by enrollment, is the only one that started in 2016, is one of 7 in phase 2, and was the 14th registered.
484 studies on the registry are indexed under Thrombocytopenia; 102 are open to participants now.
Browse Thrombocytopenia studies →3 of the 21 studies in Thrombocytopenia with a site in Poland are open now. Recruiting first, the newest first:
Jiangsu HengRui Medicine Co., Ltd. · Sites in Poland, United States, Bulgaria and 8 more countries
Ages 18+
Takeda · Sites in Poland, United States, Australia and 15 more countries
Ages 18+
Karyopharm Therapeutics Inc · Sites in Poland, United States, Belgium and 16 more countries
Ages 18+
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 66 Thrombocytopenia studies recruiting now, 44 (67%) set no upper age limit and 18 (27%) stop at 75 or younger; 10 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 8 · Phase 3 13 · Phase 4 1
First in 2000; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 66 is above the median of 54 across 336 interventional studies indexed under Thrombocytopenia.
Median enrollment 150 across the 21 interventional studies. Of the 16 that completed or were terminated, 13 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 21 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB Biopharma SRL, one of the names counted as UCB S.A.. Under that name alone:
UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.
UCB S.A. has 1 study filed under Thrombocytopenia — fewer than ten, so there is no comparison to draw.
1 of the studies in Thrombocytopenia with a site in Poland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05980806Karyopharm Therapeutics IncA Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia | 2027-06 |
Add it to your calendar (.ics) → With an account.
Among the 21 studies in Thrombocytopenia with a site in Poland, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to check if an subcutaneous (sc) infusion of UCB7665 is safe and tolerated in subjects with primary immune thrombocytopenia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subject has renal and/or liver impairment defined as:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm received 5 subcutaneous (sc) doses of UCB7665 (rozanolixizumab) 4 milligram per kilograms (mg/kg) at 1-week intervals.
Drug: UCB7665
Participants in this arm received 3 sc doses of UCB7665 (rozanolixizumab) 7 mg/kg at 1-week intervals.
Drug: UCB7665
Participants in this arm received 2 sc doses of UCB7665 (rozanolixizumab) 10 mg/kg at 1-week intervals.
Drug: UCB7665
Participants in this arm received 1 sc dose of UCB7665 (rozanolixizumab) 15 mg/kg.
Drug: UCB7665
Participants in this arm received 1 sc dose of UCB7665 (rozanolixizumab) 20 mg/kg.
Drug: UCB7665
* Intervention Type: Biological/Vaccine * Pharmaceutical Form: Powder for solution for infusion * Concentration: 100 mg/ml - Route of Administration: Subcutaneous infusion
Also known as: rozanolixizumab
Percentage of Participants Experiencing at Least One Treatment Emergent Adverse Event (TEAE) During the Study
TEAEs were defined as Adverse Events starting after the time of first Investigational Medicinal Product (IMP) administration up to and including 8 weeks after the final dose.
Time frame: From Visit 2 (Week 1) until End of Study Visit or Early Termination (up to 12 weeks after the first investigational medicinal product (IMP) administration)
The study started to enroll patients in March 2016 and concluded in February 2019.
| Milestone | UCB7665 4 mg/kg | UCB7665 7 mg/kg | UCB7665 10 mg/kg | UCB7665 15 mg/kg | UCB7665 20 mg/kg |
|---|---|---|---|---|---|
| Started | 15 | 15 | 12 | 12 | 12 |
| Completed | 14 | 15 | 12 | 12 | 12 |
| Not completed | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 | 0 | 0 |
TEAEs were defined as Adverse Events starting after the time of first Investigational Medicinal Product (IMP) administration up to and including 8 weeks after the final dose.
| percentage of participants | UCB7665 4 mg/kg (SS) | UCB7665 7 mg/kg (SS) | UCB7665 10 mg/kg (SS) | UCB7665 15 mg/kg (SS) | UCB7665 20 mg/kg (SS) |
|---|---|---|---|---|---|
| Percentage of Participants Experiencing at Least One Treatment Emergent Adverse Event (TEAE) During the Study | 80.0 | 60.0 | 58.3 | 91.7 | 100 |
Collected over Adverse events were collected from Week 1 until the End-of-Study Visit (8 weeks following the final dose) (up to 12 weeks after the first dose of IMP). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| UCB7665 4 mg/kg (SS) | 0/15 (0%) | 1/15 (6.7%) | 11/15 (73.3%) |
| UCB7665 7 mg/kg (SS) | 0/15 (0%) | 0/15 (0%) | 9/15 (60%) |
| UCB7665 10 mg/kg (SS) | 0/12 (0%) | 1/12 (8.3%) | 7/12 (58.3%) |
| UCB7665 15 mg/kg (SS) | 0/12 (0%) | 2/12 (16.7%) | 10/12 (83.3%) |
| UCB7665 20 mg/kg (SS) | 0/12 (0%) | 0/12 (0%) | 12/12 (100%) |
| Event | UCB7665 4 mg/kg (SS) | UCB7665 7 mg/kg (SS) | UCB7665 10 mg/kg (SS) | UCB7665 15 mg/kg (SS) | UCB7665 20 mg/kg (SS) |
|---|---|---|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 0/15 | 0/15 | 1/12 | 1/12 | 0/12 |
| Platelet count decreasedInvestigations | 0/15 | 0/15 | 0/12 | 1/12 | 0/12 |
| Genital haemorrhageReproductive system and breast disorders | 1/15 | 0/15 | 0/12 | 0/12 | 0/12 |
| Event | UCB7665 4 mg/kg (SS) | UCB7665 7 mg/kg (SS) | UCB7665 10 mg/kg (SS) | UCB7665 15 mg/kg (SS) | UCB7665 20 mg/kg (SS) |
|---|---|---|---|---|---|
| HeadacheNervous system disorders | 3/15 | 6/15 | 3/12 | 5/12 | 9/12 |
| VomitingGastrointestinal disorders | 0/15 | 0/15 | 0/12 | 2/12 | 4/12 |
| PyrexiaGeneral disorders | 0/15 | 0/15 | 1/12 | 1/12 | 3/12 |
| DiarrhoeaGastrointestinal disorders | 1/15 | 2/15 | 1/12 | 2/12 | 2/12 |
| ContusionInjury, poisoning and procedural complications | 0/15 | 0/15 | 0/12 | 1/12 | 2/12 |
| Joint swellingMusculoskeletal and connective tissue disorders | 0/15 | 0/15 | 0/12 | 0/12 | 2/12 |
| AnaemiaBlood and lymphatic system disorders | 1/15 | 1/15 | 0/12 | 1/12 | 0/12 |
| Immune thrombocytopenic purpuraBlood and lymphatic system disorders | 0/15 | 0/15 | 0/12 | 0/12 | 1/12 |
| Ear painEar and labyrinth disorders | 0/15 | 0/15 | 1/12 | 0/12 | 0/12 |
| NauseaGastrointestinal disorders | 1/15 | 0/15 | 1/12 | 1/12 | 0/12 |
Baseline Characteristics refer to the Safety Set which consisted of all study participants who had received at least 1 infusion (full or partial infusion) of rozanolixizumab and was used for the analysis of safety data.
| Age, Categorical(Participants) | UCB7665 4 mg/kg | UCB7665 7 mg/kg | UCB7665 10 mg/kg | UCB7665 15 mg/kg | UCB7665 20 mg/kg | Total Title |
|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 7 | 14 | 10 | 11 | 7 | 49 |
| >=65 years | 8 | 1 | 2 | 1 | 5 | 17 |
| Age, Continuous(years) | UCB7665 4 mg/kg | UCB7665 7 mg/kg | UCB7665 10 mg/kg | UCB7665 15 mg/kg | UCB7665 20 mg/kg | Total Title |
|---|---|---|---|---|---|---|
| Mean | 59.1 ± 18.4 | 46.0 ± 15.9 | 46.3 ± 16.8 | 45.8 ± 14.6 | 56.1 ± 18.2 | 50.8 ± 17.4 |
| Sex: Female, Male(Participants) | UCB7665 4 mg/kg | UCB7665 7 mg/kg | UCB7665 10 mg/kg | UCB7665 15 mg/kg | UCB7665 20 mg/kg | Total Title |
|---|---|---|---|---|---|---|
| Female | 8 | 11 | 7 | 7 | 9 | 42 |
| Male | 7 | 4 | 5 | 5 | 3 | 24 |
| Race/Ethnicity, Customized(Participants) | UCB7665 4 mg/kg | UCB7665 7 mg/kg | UCB7665 10 mg/kg | UCB7665 15 mg/kg | UCB7665 20 mg/kg | Total Title |
|---|---|---|---|---|---|---|
| Asian | 2 | 0 | 0 | 0 | 0 | 2 |
| White | 13 | 15 | 12 | 12 | 12 | 64 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2016 to primary completion in Feb 2019, 35 months.
Results were first posted in Jan 2024, 4 years 11 months after primary completion.
Of 54 phase 2 interventional studies under Thrombocytopenia, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 81. This study's 35 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rozanolixizumab